ABSTRACT Purpose: The purpose of this study was to confirm the hypothesis that a site-II-to-site-I displacement takes place when some nonsteroidal antiinflammatory drugs are displaced by another drug from their high-affinity binding site to a site of lower affinity on human serum albumin (HSA). Methods: Diclofenac, sodium salt, was used as a representative example because of its prominent reversal of the Cotton effect. Effects of site-specific drugs on the free fraction of diclofenac were determined by equilibrium dialysis, and effects on induced circular dichroism (CD) of diclofenac bound to HSA were studied by CD and CD simulation techniques. Results: Ibuprofen, a site-II-specific drug, altered the CD spectrum of the diclofenac-HSA complex at a molar ratio of 0.5 : 1 to that obtained at a higher ratio (5:1) without ibuprofen. The induced CD spectrum obtained in the presence of ibuprofen was very similar to one that assumed that all diclofenac displaced from its high-affinity binding site (site II) became rebound to a lower-affinity site (site I). The rebinding could be influenced by a free energy linkage between the two sites which would make site I (or parts thereof) more suitable for diclofenac binding.
INTRODUCTION
The pharmacokinetic properties of exogenous and endogenous compounds can be influenced by reversible binding to human serum albumin (HSA), which is thought to be one of the primary determinants of the pharmacokinetic properties of drugs [1] [2] [3] [4] . Therefore, when evaluating interactions between drugs, it is important to be aware of possible identities of their binding sites on the protein, because any alteration in drug-binding to HSA, including binding of the nonsteroidal antiinflammatory drugs ( NSAIDs), could lead to a change in pharmacokinetic properties. In a previous report, we proposed an interesting model for such interactions, which we referred to as site-to-site displacement. This model was based on the observation that carprofen, a carboxyl group containing site II-specific NSAID, underwent a site-II-to-site-I displacement when displaced from its high-affinity site to its low-affinity site in the presence of ibuprofen, another site-II-specific NSAID [5] . Although Chamouard et al. [6] reported a similar phenomenon on the basis of circular dichroism (CD) studies of the binding of diclofenac in the presence of another site II-specific drug, available CD simulation data do not confirm this phenomenon. A CD simulation technique was used to confirm the hypothesis that the reversal of the CD spectra of carprofen and diclofenac by ibuprofen was due to siteto-site displacement. Diclofenac was used as a representative example, because the reversal of the sign of the Cotton effect for this compound is prominent, and because a large difference exists between the highaffinity and low-affinity association constants.
MATERIALS AND METHODS

Materials
HSA (fraction V) was donated by the Chemo-SeraTherapeutic Research Institute (Kumamoto, Japan) and was defatted with activated charcoal using the method originally described by Chen [ 7] but with some modifications as described previously [8] . Dansyl-Lasparagine (DNSA) was purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.) and dansylsarcosin (DNSS) was purchased from Tokyo Kasei Kogyo Co. (Tokyo, Japan). Ibuprofen (Kaken Pharmaceuticals Co., Tokyo, Japan), diclofenac, sodium salt, (Taiyo Pharmaceutical Industry, Takayama, Japan), and warfarin, potassium salt, (Eisai Co., Tokyo, Japan) were obtained as pure substances from their manufacturers. All other reagents were of analytical grade. The buffer was prepared with sodium phosphate dibasic and sodium phosphate monobasic salts.
CD measurements
CD measurements of the diclofenac-HSA complex at different drug-to-HSA ratios (0.2:1 to 5:1) (40 µM protein) were carried out on a Jasco J-600 spectropolarimeter (Tokyo, Japan), using a 10 mm cell at pH 7.4 and 25°C. Different ratios (0 to 5) of ibuprofen to HSA (40µM) were used to measure the effect of that drug on the induced CD spectra of the diclofenac-HSA system (0.5:1) at pH 7.4 and 25°C. In all cases the medium contained 67 mmol/L sodium phosphate as a buffer. The induced CD is defined as the CD of the drug-HSA mixture minus the CD of HSA alone at the same wavelength and is expressed as ellipticity in degrees.
Equilibrium dialysis (ED)
ED experiments were performed using a 2-mL Sanko plastic dialysis cell (Fukuoka, Japan). The two cell compartments were separated by a Visking cellulose membrane. To determine binding, aliquots (1.5 mL) of various ratios of drug-HSA mixtures (HSA, 40 µM; drug, 20-400 µM) were dialyzed at 25°C for 13 hours against the same volume of buffer solution (67 mmol/L sodium phosphate)., Adsorption of the drugs to the dialysis membrane and cell was insignificant at the concentrations used.. Further control experiments, using protein-free solutions, showed that the Visking membranes were fully permeable to the drugs, and that equilibrium was established within the designated period of time. After equilibrium was reached, the free concentrations of diclofenac and ibuprofen were determined by high-performance liquid chromatography (HPLC). The HPLC system consisted of a Hitachi 655A-11 pump and a Hitachi 655A variable UV monitor. A column of LiChrosorb RP-18 (Cica Merk, Tokyo, Japan) was used as a stationary phase for the analyses. 
Treatment of Data
Binding parameters were estimated by fitting a theoretical curve based on the following equation to the experimental data by using MULTI, a non-linear least squares computer program [9] .
(1)
In this equation, r is the number of moles of drug bound per mole of protein. C b and C f are the bound and unbound drug concentrations, respectively, and P t is the total protein concentration. K i is the association constant and n i is the number of binding sites for the ith class of binding sites.
A simple competition between two drugs for identical protein binding sites was analyzed using the methodology described by Kragh-Hansen [2] .
CD simulation
The mathematical calculations for the CD simulation that were used in this study are given below.
where Θ obs is the total CD ellipticity, C i and [Θ i ] are the concentration of bound drug and the molar ellipticity for the ith class of binding sites, respectively. [Θ h ] is the molar ellipticity at the highaffinity site, and [Θ l ] is the mean molar ellipticitiy at low-affinity sites, whereas C h and C l are the concentrations of the drug bound at the high-and low-affinity sites, respectively. For a theoretical calculation of C h and C l , the following equation was used.
In Equation 3 , n h and n l are the numbers of high and low affinity binding sites, and K h and K l are the high and low affinity association constants. In this
It is known that:
where C t is the total drug concentration. In the case of displacement of two drugs binding to one site, the value of the concentration of bound drug (A b ) for the displaced one can be theoretically calculated in the following manner.
where K A and A f are the association constant and the free concentration, respectively, for drug A (displaced drug), whereas K B and B f are the association constant and the free concentration, respectively for drug B (displacing drug).
Equation 7 can be written as
where a=A t -A b .
Equation 8 can be written as
where b=B t -B b .
Equation 10 can be transformed to Equation 11.
where g=K A P t -K A A t -1 . Since the values of h, i, j and k are constants, the value for A b can be calculated from the value derived from Equation 13. In the case of displacement of drug A by drug B, A b represents C h plus C l . 
RESULTS AND DISCUSSION
Interaction of diclofenac with HSA
Identical concentrations of HSA were used for all the CD and ED experiments. The CD spectra of the complexes of different ratios of diclofenac and HSA are shown in Figure 1 . Since diclofenac itself is not optically active, and HSA does not give rise to any Cotton effects at the wavelengths used, there can be no doubt that the observed Cotton effects are extrinsic in origin. In all cases, large amplitude CD bands were generated, when diclofenac had bound to HSA. At the lowest molar ratio of drug to HSA (0.2:1) when diclofenac was largely bound to its primary binding site, a negative band, centered at 282 nm, and a weaker positive band, centered at 315 nm, were induced. Also at slightly higher diclofenac-to-HSA ratios (0.5:1 and 1:1), strong negative Cotton effects were observed at 282 nm. In addition, the shapes of the CD spectra were qualitatively the same. However, at a higher ratio of diclofenac to HSA (2:1), a situation in which binding to the lowaffinity sites also takes place, a dramatic change in the CD spectrum was generated, resulting in the production of a new positive band around 280 nm and a small negative band at 300 nm. The amplitude of the band at 315 nm was also reduced. At still higher ratios of diclofenac to HSA (3:1,4:1, and 5:1), the same pattern in the CD spectra was obtained, showing a positive maximum at about 280 nm and a negative maximum at about 310 nm. This unequivocally indicates that binding of diclofenac to its high and low affinity binding sites on HSA shows completely different Cotton effects due to differences in the spatial orientation in these sites.
The binding parameters, determined by ED, for the interaction of diclofenac with HSA are included in Table 2 . Table 2 . Binding parameters for diclofenac and ibuprofen bound to HSA, as determined by equilibrium dialysis, at pH 7.4 and 250C 
Site-to-site displacement of albuminbound diclofenac
The effect of increasing the ibuprofen-to-HSA ratio on the CD spectrum of the diclofenac-HSA complex (0.5:1) is shown in Figure 2 . In the presence of a high concentration of ibuprofen (ibuprofen:HSA 5:1), the sign of the Cotton effect at 290 nm was completely reversed. This spectrum is similar to those obtained for the diclofenac-HSA complexes (3:1 or 5:1) in the absence of ibuprofen (Figure 1) . Ibuprofen itself showed no measurable CD spectrum under the present experimental conditions.
The effects of different concentrations of ibuprofen on the free fraction (%) of diclofenac-HSA at a molar ratio of 1:2, in the absence and presence of a constant concentration of warfarin or phenylbutazone, were determined by ED and are shown in Figure 3 . 
¨ ). (---):
A theoretical curve assuming a simple competition between diclofenac and ibuprofen at site II on HSA without rebinding of diclofenac to the low-affinity site(s). The following concentrations were used: HSA, 40µ M; diclofenac, 20 µ M; warfarin, 20 µ M and phenylbutazone, 20µ M.
In the absence of warfarin and phenylbutazone the free fraction of diclofenac increased from 0.80 % to approximately 3% with the gradual addition of ibuprofen (Insert, Figure 3 ). However, the experimentally determined free fractions were much lower than those calculated (broken curve) assuming simple competition between the two drugs for the same high-affinity site on HSA. This result suggested that diclofenac displaced from its highaffinity binding site could rebind to another site. Figure 3 also shows that the free fractions of diclofenac caused by ibuprofen are higher when warfarin or phenylbutazone is present in a relatively low concentration.
The increments of the free fractions of diclofenac were higher in the presence of phenylbutazone than in the presence of warfarin (Figure 3) . The same pattern was observed throughout the course of displacement. Basically the same effect was observed in the absence of ibuprofen (Figure 4) . 
Circular dichroism (CD) simulation
To further establish the validity of the site-to-site displacement (see Material and Methods for details), CD curves were constructed for the diclofenac HSA complex (0.5:1), in the presence and absence of ibuprofen, by using the observed ellipticity at both the high-and low-affinity sites ([Θ] multiplied by the respective concentration). Figure 5 shows the results of the CD simulation. Curve a was obtained from the experimental data in the absence of ibuprofen, and curve b was obtained from this data in the presence of ibuprofen; curves a' and b' are the theoretical curves for the same conditions. Curve b'' denotes the theoretical curve in the presence of ibuprofen, assuming no rebinding of displaced diclofenac.
CONCLUSION
The nonlinearity of the Scatchard plots (data not shown) suggested the presence of at least two classes of binding sites for diclofenac and ibuprofen on HSA. As shown in Table 2 , diclofenac exhibited a high association constant (K h =3.3 x 10 6 M -1 ) for the high-affinity site on HSA, similar to that of ibuprofen. Furthermore, diclofenac has a more than 10-fold lower association constant (K l =5.4 x 10 4 M -1 ) for the low-affinity sites, a finding that is in general agreement with the results reported earlier by Chamouard et al. [6] . Diclofenac, like carprofen and ibuprofen, binds to site II with a very high association constant.
The CD spectra of diclofenac bound to HSA at low and high ratios of drug to protein were very different. The single high-affinity binding site on HSA might almost totally contribute to the induced CD at a low ratio of drug to protein (1:2). However, at higher ratios several low-affinity binding sites also contribute to the extrinsic CD, and it may be that their contribution to CD could be larger than that of the high-affinity site. Ibuprofen altered the CD spectrum of the diclofenac-HSA complex (0.5:1) to those which were obtained at higher drugto-HSA ratios (for example, 5:1) in the absence of ibuprofen. Results of the ED experiments were helpful in analyzing the mechanism of generation of these experimentally determined CD data. Although, the ED experiments were not as useful in explaining the CD data, their results can be used to make some predictions about site-to-site displacement. For example, at low ratios of drug to albumin, most of the diclofenac molecules might bind to the high-affinity site and ibuprofen could at first be bound to the free HSA molecules ( Figure  6A ).
The following ibuprofen molecules being bound displace the diclofenac bound to its high-affinity site and, finally , most of the displaced diclofenac molecules rebind to the low-affinity site. An additional displacement of diclofenac is observed in the presence of low concentrations of warfarin and phenylbutazone. The finding that phenylbutazone causes a larger displacement than warfarin might be due to the differences in association constants (warfarin:~2. ). These results support the proposal that diclofenac is being rebound at site I.
A priori, it is also possible that the characteristic CD spectra of the diclofenac-HSA-ibuprofen system could be due to allosteric modifications introduced by the bound ibuprofen molecule. However, increases in temperature (data not shown) and pH ( Table 3) failed to cause a significant change in the CD spectrum of the diclofenac-HSA complex, suggesting that the alteration in the CD spectra was not a result of microenvironmental changes in the diclofenac binding site on HSA. It is also possible that the diclofenac molecule bound to site II on HSA could form a complex (a diclofenac-HSA-ibuprofen ternary complex or a diclofenac-HSA-diclofenac ternary complex) with another diclofenac or ibuprofen molecule through stacking or electron transfer. However, this is not possible for diclofenac and ibuprofen to simultaneously bind to HSA, because they have a common binding site. In addition, according to spectrophotometric studies performed at 278 nm, no self-association of diclofenac takes place in aqueous solution (without HSA) under the study conditions because the absorbancy coefficient (8.3 x 10 3 M -1 x cm -1 ) was found to be constant in the concentration range 2 x 10 -6 M -1 x 10 -4 M.
To confirm our hypothesis that the reversal of the CD spectra of diclofenac bound to HSA in the presence of ibuprofen was due to site-to-site displacement, we used a CD simulation technique. Figure 5 compares the experimentally determined CD curves with the curves based on theoretical values, obtained using the CD simulation technique. Curve a (solid line) is the CD curve for the diclofenac-HSA complex at a 5:1 drug-to-HSA ratio. Curve a' (dotted line) represents a CD curve obtained from the theoretical values. When the effect of ibuprofen, as a displacer, was taken into consideration, curve b (solid line) was obtained from the experimental data. The theoretical values elicited curve b' (dotted line), which closely resembles the curve derived from the experimental data, further suggesting that the reversal of the Cotton effect sign in the presence of ibuprofen is very likely due to a site-to-site displacement of diclofenac by ibuprofen. If there had been no rebinding of diclofenac, the theoretically calculated CD curve would resemble curve b'', which is very different from curve b. These data further support the hypothesis that diclofenac shows site-to-site displacement in the presence of ibuprofen.
Although it is possible that all of the displaced drug from site II simply rebinds to another site, our proposal might be a little too simple, because the rebinding could be affected by a free energy linkage between ibuprofen bound to site II and diclofenac bound to site I. The free energy linkage between the two sites could result in conformational changes in site I (or parts thereof), rendering it more suitable for diclofenac binding ( Figure 6B ) (for reviews on this topic, see [ 2, 3] ). A finding supporting this proposal is that ibuprofen causes an enhancement of the binding of the site I-drug warfarin [ 12] . However, this hypothesis based upon the free energy linkage cannot alone explain the CD data. Therefore, it is reasonable to hypothesize that siteto-site displacement from site II to site I as well as free energy linkage between the sites caused the CD spectra. However, we cannot clarify the relative magnitudes of the above factors in detail from these limited data.
For drugs such as diclofenac and carprofen, whose binding to HSA is in excess of 99%, an increase in the free fraction of only 1% doubles the amount of drug available for pharmacological activity. Therefore, a quantitative change of even 1% in binding can be expected to have an effect on its disposition. Thus, care should be exercised in calculating the free concentration of drugs that show site-to-site displacement in the presence of other drugs, since the results can be misleading.
In conclusion, we have confirmed the existence of a significant siteII-to-siteI displacement, which is pharmacologically important. When studying drugdrug interactions, more specifically drug displacements, the possibility of site-to-site displacement should be considered, because it can cause significant differences between the free concentrations of a displaced drug. Although the results presented here are significant, a more detailed study, including in vivo experiments, is needed to predict the actual changes in pharmacokinetic properties caused by this site-tosite displacement.
